BeiGene, Ltd. announced that the board of directors of the Company (the "Board") has re-designated Mr. Anthony C. Hooper ("Mr. Hooper") as an independent non- executive director effective from April 17, 2023 (the "Redesignation"). Previously, Mr. Hooper was a non-executive director. Following the Re-designation, Mr. Hooper will remain a member of the Board, the audit committee and the nominating and corporate governance committee and the chairman of the commercial and medical affairs advisory committee of the Board.

As disclosed in the circular to shareholders dated November 29, 2019, in connection with the share purchase agreement entered into by the Company with Amgen Inc. ("Amgen"), a substantial shareholder of the Company at the time of this announcement, Amgen had a contractual right to designate a director to the Board of the Company and named Mr. Hooper as its designee. Mr. Hooper was elected as a director by shareholders on December 27, 2019 and he formally joined the Board in January 2020 as a non-executive director. In June 2022, Mr. Hooper was re-elected by shareholders as a director for a three-year term ending in 2025.

On January 30, 2023, Amgen relinquished its director designation right and Mr. Hooper ceased to be an Amgen director designee. Mr. Anthony C. Hooper has served as a member of the Board since January 2020. Mr. Hooper retired from Amgen in January 2020, where he was Executive Vice President from September 2018 to January 2020, and Executive Vice President, Global Commercial Operations from 2011 to August 2018.

From 2010 to 2011, Mr. Hooper was Senior Vice President, Commercial Operations and President, U.S., Japan and Intercontinental of Bristol Myers Squibb Company (BMS). From 2009 to 2010, Mr. Hooper was President, Americas of BMS. From 2004 to 2009, Mr. Hooper was President, U.S. Pharmaceuticals, Worldwide Pharmaceuticals Group, a division of BMS. Prior to that, Mr. Hooper held various senior leadership positions at BMS. Prior to joining BMS, Mr. Hooper was Assistant Vice President of Global Marketing for Wyeth Laboratories. Mr. Hooper earned law and MBA degrees from the University of South Africa in 1978 and 1988, respectively.

Mr. Hooper serves on the board of MannKind Corporation. Mr. Hooper is a consultant to Amgen.